Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 5
2000 6
2001 3
2002 6
2004 4
2005 3
2006 4
2007 3
2008 2
2009 4
2011 2
2012 3
2014 1
2017 1
2018 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Neramexane.
[No authors listed] [No authors listed] Drugs R D. 2002;3(1):19-20. doi: 10.2165/00126839-200203010-00003. Drugs R D. 2002. PMID: 11881523 Review. No abstract available.
Neramexane (merz pharmaceuticals/forest laboratories).
Rammes G, Schierloh A. Rammes G, et al. IDrugs. 2006 Feb;9(2):128-35. IDrugs. 2006. PMID: 16523403 Review.
Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and …
Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potent …
Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications.
Rammes G. Rammes G. Expert Rev Clin Pharmacol. 2009 May;2(3):231-8. doi: 10.1586/ecp.09.7. Expert Rev Clin Pharmacol. 2009. PMID: 24410702
Although the predicted therapeutic doses of neramexane were very well tolerated in male volunteers, unfortunately, recent Phase II/III clinical trials for moderate-to-severe AD delivered contradictory results. Neramexane also failed in a recent randomized controlled …
Although the predicted therapeutic doses of neramexane were very well tolerated in male volunteers, unfortunately, recent Phase II/II …
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
Pakri Mohamed RM, Kumar J, Ahmad SU, Mohamed IN. Pakri Mohamed RM, et al. Curr Drug Targets. 2018;19(12):1378-1390. doi: 10.2174/1389450119666180523092534. Curr Drug Targets. 2018. PMID: 29788886 Review.
This review article summarizes the novel pharmacotherapeutic approaches used in the treatment of alcohol addiction by focusing on the drugs, which include neramexane, gabapentin, baclofen, aripiprazole, nalmafene, and quetiapine....
This review article summarizes the novel pharmacotherapeutic approaches used in the treatment of alcohol addiction by focusing on the drugs, …
Effect of neramexane on ethanol dependence and reinforcement.
Kotlinska J, Biala G, Rafalski P, Bochenski M, Danysz W. Kotlinska J, et al. Eur J Pharmacol. 2004 Oct 25;503(1-3):95-8. doi: 10.1016/j.ejphar.2004.09.036. Eur J Pharmacol. 2004. PMID: 15496302
Neramexane hydrochloride (3.5 mg/kg and higher) inhibited both the development and expression of ethanol dependence. ...Our data support therapeutic potential of neramexane as a treatment for alcohol abuse....
Neramexane hydrochloride (3.5 mg/kg and higher) inhibited both the development and expression of ethanol dependence. ...Our data supp …
Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors.
Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, Millar NS, Elgoyhen AB. Plazas PV, et al. Eur J Pharmacol. 2007 Jul 2;566(1-3):11-9. doi: 10.1016/j.ejphar.2007.03.026. Epub 2007 Mar 24. Eur J Pharmacol. 2007. PMID: 17466293
Our results indicate that both compounds block acetylcholine-evoked responses at micromolar concentrations with a rank order of potency of neramexane>memantine, P<0.05. Block by neramexane of acetylcholine responses was not overcome at high concentrations of t …
Our results indicate that both compounds block acetylcholine-evoked responses at micromolar concentrations with a rank order of potency of …
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R. Bachteler D, et al. Neuropsychopharmacology. 2005 Jun;30(6):1104-10. doi: 10.1038/sj.npp.1300657. Neuropsychopharmacology. 2005. PMID: 15668725
This study examines, for the first time, the effects of acamprosate and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist neramexane on ethanol-seeking induced by alcohol-related environmental stimuli in an animal model of relapse. ...However, a slight re …
This study examines, for the first time, the effects of acamprosate and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist …
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.
Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM. Zoladz PR, et al. Pharmacol Biochem Behav. 2006 Oct;85(2):298-306. doi: 10.1016/j.pbb.2006.08.011. Epub 2006 Oct 11. Pharmacol Biochem Behav. 2006. PMID: 17045636
Memantine is approved for the treatment of Alzheimer's disease, and neramexane is currently under development for this indication. Therefore, the present study provided a comparative assessment of the effects of equimolar doses of memantine and neramexane on spatial …
Memantine is approved for the treatment of Alzheimer's disease, and neramexane is currently under development for this indication. Th …
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus.
Suckfüll M, Althaus M, Ellers-Lenz B, Gebauer A, Görtelmeyer R, Jastreboff PJ, Moebius HJ, Rosenberg T, Russ H, Wirth Y, Krueger H. Suckfüll M, et al. BMC Ear Nose Throat Disord. 2011 Jan 11;11:1. doi: 10.1186/1472-6815-11-1. BMC Ear Nose Throat Disord. 2011. PMID: 21223542 Free PMC article.
RESULTS: Compared with placebo, the largest improvement was achieved in the 50 mg/d neramexane group, followed by the 75 mg/d neramexane group. This treatment difference did not reach statistical significance at the pre-defined endpoint in Week 16 (p = 0.098 for 50 …
RESULTS: Compared with placebo, the largest improvement was achieved in the 50 mg/d neramexane group, followed by the 75 mg/d nera …
Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia.
Klein T, Magerl W, Hanschmann A, Althaus M, Treede RD. Klein T, et al. Eur J Pain. 2008 Jan;12(1):17-29. doi: 10.1016/j.ejpain.2007.02.002. Epub 2007 Apr 20. Eur J Pain. 2008. PMID: 17449306 Clinical Trial.
Eighteen healthy subjects received either a single dose of neramexane (40 mg p.o.), flupirtine (100 mg) or placebo in a double-blind, randomized, cross-over study. Pain evoked by intradermal capsaicin injection as well as pain evoked by pinpricks was significantly reduced …
Eighteen healthy subjects received either a single dose of neramexane (40 mg p.o.), flupirtine (100 mg) or placebo in a double-blind, …
49 results